

Type 1 Diabetes Overview

- Type I diabetes (T1D) is a life-long auto-immune disease requiring constant blood glucose (BG) monitoring, frequent injections of insulin, and lifelong maintenance to minimize complications
- BG excursions negatively impact every single system and organ in the body
- Frequent exams, tests, and visits to a large medical support team are required
- T1D is a leading causes of kidney failure,
 blindness, amputation, and cardiovascular disease



Type 1 Diabetes Overview

T1D Industry annual costs:

- \$10B in United States
- **\$100B** globally
- \$10k average in diabetes related medical costs per year,
- Estimated ~2M Type 1 diabetics in USA, estimated ~18M globally
- Average lifespan reduced by ~8-18 years, with good management
- Average of 300+ minutes per day required just to maintain T1D
- T1D BG levels are affected by >40 immeasurable variables, making disease management very complex

T1CURE Leadership



Ben R. Savage, CEO

A San Diego native since 1980, Ben was diagnosed with T1D in 2000. In his decades as a T1D, Ben has participated in numerous device and medication studies, many requiring the wearing of multiple continuous glucose monitors and testing new insulin formulations, all with the goal of making life with the disease more manageable. Ben's background includes engineering, manufacturing, and testing CGM devices, smart insulin delivery systems, and new product introduction for the NIH and in support of FDA approval as well as 510(k) fast track approval for life-saving medical devices. He has also directly supported a major diabetes device manufacturer, receiving multiple awards in his short tenure. Ben has more than a decade of experience in fundraising and service on the board of directors at The Way Back non-profit. Additionally, he has served as Vice Chair on multiple professional trade councils. Ben wishes for nothing more than to live free of disease.



Timothy R. Snowball, Esq. COO

Tim Snowball is a big believer in overcoming the odds. Born and raised in San Diego, Tim spent most of his life in Southern California before moving to the Bay Area to complete his undergraduate education at UC Berkeley, and later attend law school at The George Washington University Law School in Washington, DC. Since completing his JD and successfully passing the California bar in 2017, Tim has spent the entirety of his career working in the non-profit field defending the constitutional rights of average Americans. He has participated in hundreds of media interviews, written multiple viral op-eds and blog posts, and regularly delivers speeches and other presentations to groups across California. Not only does Tim have friends and family whose lives are impacted by Type 1 diabetes, he is also a big believer in overcoming the odds. When he is not in court or the classroom, you can find Tim in the gym, with his nose stuck in a book, or spending time with his loved ones.



Frankie Sandberg, Dir. Events

A San Diego native since 1980, Frankie was diagnosed with T1D in 2017, following a lengthy, painful and mysterious illness that ultimately resulted in inability to work. Close friends to Frankie believed that he was near death after losing 130 lbs due to undiagnosed T1D and severe nerve damage. Frankie is recovering, but still requires pain management and repair to his extremities due to years of undiagnosed blood glucose excursions. Frankie is loved by many in his community and has proactively began treatment to his disease, shared his story with loved ones and is eager to support this foundation and its purpose. Frankie's family business in precious metals & collectibles sales, crypto currency investment and hosting fundraising events will be of great value for T1CURE and the millions of T1D's that need help.

T1CURE Initiatives

- Communicate information helpful to T1Ds and their families
- Access affordable care for all T1Ds
- Fund promising, scalable, affordable studies for cures
- Empower T1Ds and give them a voice in shaping FDA laws and treatment

The T1D NFP Landscape: Conflicts & Gaps

- Biggest NFPs use only 2-7% for cure R&D
- Venture philanthropy focus on ROI, not PT outcomes
- Largest donors are insulin & device OEMs= conflict of interests
 - Three insulin producers control 90%+ global insulin supply
- Research grants biggest NFPs 2000-2021: down from 80% to 33%
- Administrative costs and executive compensation up >20%
- Virtually no generic or combination therapies studies funded
- Largest NFPs and venture philanthropy pushes towards one thing: a more profitable disease and greater burden of cost to the T1D and their families

Case in point: new "vaccine" delays T1D ~2 years, costs \$200K



The T1Cure Difference

- We fill the gaps between NIH probes->clinical trials->available pharmaceuticals
- Our mission is to find, fund, and facilitate cures for T1D
- T1D leadership ensures alignment with our purpose
- ALL T1Ds are supported; not just the well-insured
- Generic combination therapy is under-studied and under-funded
- No funding from big pharmaceutical companies = no conflict of interests
- Studies are selected based on key metrics in support of our mission:
 - Effectiveness
 - Safety
 - Scalability
 - Affordability

T1Cure Founder's Fund

- ALL donations are 100% tax-deductible
- YOUR gift will advance science, education, and care for ALL T1Ds
- Advances in research, care and FDA regulations will help not only T1Ds and their families, but can help shape the future of healthcare developments
- Donations to generic studies are needed more in comparison to more profitable drugs
- Pay.t1cure.org



TICURE C/O BENJAMIN RUDOLPH SAVAGE

Employer ID numbe 84-4631046 Person to contact: Name: Joan Kiser ID number: 31217 Telephone: 877-829-5500 Accounting period ending: December 31 Public charity status 170(b)(1)(A)(vi) Form 990 / 990-EZ / 990-N required Effective date of exemptio June 4, 2020 Contribution deductibility Addendum applies 2605357900451

01/09/2022

Dear Applicant:

We're pleased to tell you we determined you're exempt from federal income tax under Internal Revenue Code (IRC) Section 501(c)(3). Donors can deduct contributions they make to you under IRC Section 170. You're also qualified to receive tax deductible bequests, devises, transfers or gifts under Section 2055, 2106, or 2522. This letter could help resolve questions on your exempt status, Please Keep it for your records.

Organizations exempt under IRC Section 501(c)(3) are further classified as either public charities or private foundations. We determined you're a public charity under the IRC Section listed at the top of this letter.

If we indicated at the top of this letter that you're required to file Form 990/990-EZ/990-N, our records show you're required to file an annual information return (Form 990 or Form 990-EZ) or electronic notice (Form 990-N, the e-Postcard). If you don't file a required return or notice for three consecutive years, your exempt status will be automatically revoked.

If we indicated at the top of this letter that an addendum applies, the enclosed addendum is an integral part of this letter.

For important information about your responsibilities as a tax-exempt organization, go to www.irs.gov/charities. Enter "4221-PC" in the search bar to view Publication 4221-PC, Compliance Guide for 501(c)(3) Public Charities, which describes your recordkeeping, reporting, and disclosure requirements.

Sincerely,

Apphae a - arcetta

Stephen A. Martin

Director, Exempt Organizations
Rulings and Agreements

Letter 947 (Rev. 2-2020 Catalog Number 35152P

2022 Plan Phase I: Communicate & Empower

T1Cure operations:

- Graphics and marketing strategy by Sprouts Stages, courtesy Simon Trask
- Website: <u>www.t1cure.org</u>
- LinkedIn company profile, Reddit sub, Instagram, Facebook, Medium blog
- Merchandise: polos, jerseys, water bottles

Studies funded:

Levicure stage I

FDA activities performed:

- Docket FDA-2013-D-1445 for CGM OTC availability
- Insulin Act petition seeks to cap insulin prices at \$35



Levicure's proprietary Triple Therapy has shown long-term remission in T1D patients in a pilot retrospective study in Israel

Triple Therapy is a combination of 2 FDA approved drugs and a supplement: DPP4i + PPI + GABA



150 NOD mice model



T1D retrospective study (19 patients) Israeli clinic



Triple Therapy benefits



Significantly lower blood glucose and insulin demands



33% complete remission



Safe



55% complete remission



60% lower insulin demands



Extensively researched components



Significantly higher C-peptide levels and own insulin secretion



Reduced hyperglycemia time-inrange by 31%




Patented formula



Significantly superior to all double-combinations




Reduced HbA1c by 25%





100% prevention after 28 days of treatment administration



2023 Plan Phase II

Expand fundraising events to support key studies, operations and projects:

- Run/walk event
- Dinner/restaurant event
- Twitch gaming event
- YouTube partners & possible channel

Guidelines Project:

- Please see next slide
- "What to do if you run out of insulin" awarded Reddit Gold & Faith in Humanity awards

Continuously gage new T1D R&D studies, projects, FDA activities, and how to best serve T1Ds in the immediate and long term

T1D Guidelines Project

Series for new (and existing) T1Ds to include:

- What to do if you run out of insulin (already drafted)
- Picking the right endocrinologist and medical team
- Disaster Preparedness
- T1D technology guide (CGM, meter, pump, pens and more)
- Diet, nutrition, and exercise
- Discrimination prevention (legal)
- Managing psychological and emotional impacts of T1D
- T1D terms and definitions
- Guidelines will be available for download and sharing
- Local endocrinologists, T1Ds, and experts share input, and will have access to all guidelines
- QR code stickers and literature will be made available for distribution
- Budget is \$60k total, \$15k committed, \$45k remaining
- Completion Q3 2023

2024 and Beyond Plan Phase III



- Fund later-phase studies until proven effective, safe and scalable
- Ensure promising solutions make it to the T1D community
- Continue to support insulin, CGM and supply cost reductions until a working cure is available to all T1Ds
- Continue providing content, guides, videos, and materials vital to living successfully with T1D until a working cure is distributed

Our partners



Jonathan Leavitt Head of the JFL Fund at Marin Community Foundation



Albertsons VONS PAVILIONS

-Foundation-

LEVICURE

REVERSE THE IRREVERSIBLE

THANK YOU!

To Make Diabetes History"

EID: 84-4631046 pay.t1cure.org

www.t1cure.org ben@t1cure.org

Instagram: @t1cure Reddit: r/t1cure